The Science of MS Management: Update on Progressive Forms of Multiple Sclerosis

Stuart SchlossmanMS Research Study and Reports, SPMS-PPMS News

The Science of MS Management: Update on Progressive Forms of Multiple SclerosisCorey C. Ford, MD, PhD; Emmannuelle Waubant, MD, PhD
CME/CE Released: 12/31/2013; Valid for credit through 12/31/2014
Faculty and Disclosures
Corey C. Ford, MD, PhDDr. Ford has disclosed the following financial relationships:Sources of Funding for Research: Biogen Idec, Elan, Genentech, Genzyme, Janssen, Novartis, Ono Pharmaceutical, Sanofi Aventis, Serono, and Teva CNS.Consulting Agreements: Biogen Idec, Novartis, and Teva CNS.Emmanuelle Waubant, MD, PhDDr. Waubant has disclosed the following financial relationships:Consulting Agreements: Genentech, Novartis, Roche, Sanofi Aventis/Genzyme. ReviewerLaurie Scudder, DNP, NPLaurie Scudder has disclosed no relevant financial relationships.Planners and ManagersThe following planners and managers have disclosed no relevant financial relationships: Joseph J. D’Onofrio, Frank Marino, Nancy Monson, Katherine Wandersee.
Target Audience
This publication is targeted to neurologists who have an interest in treating multiple sclerosis (MS).
Learning Objectives
Upon completion of this educational activity, the participant should be able to:

  • Identify currently recognized progressive forms of multiple sclerosis (MS) and explain their relationship to each other and to relapsing-remitting MS
  • Examine recommendations and practice patterns for the use of disease-modifying therapy in patients with progressive forms of disease
  • Discuss findings of previous studies of approved MS therapies in progressive forms of MS
  • Analyze recent research studies to evaluate the potential of novel agents and standard therapies in neuroprotection and neurorepair in progressive forms of MS
Disclosure
Disclosure of Non-endorsement of ProductsApproval does not imply endorsement by the CMSC or ACCME of any commercial products discussed in conjunction with an educational activity.Disclosure of Unlabeled UseThis CME activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Teva CNS, and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC, Teva CNS, or Delaware Media Group.DisclaimerParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
Accreditation and Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Consortium of Multiple Sclerosis Centers (CMSC) and the Delaware Media Group. The CMSC is accredited by the ACCME to provide continuing medical education for physicians.The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Release Date: December 31, 2013Credit for this program expires on December 31, 2014.
Method of Participation
Follow these steps to earn CME credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. The CMSC encourages you to complete the Activity Evaluation to provide feedback for future programming.

Code: CMSC-DELMED 2013/3
Privacy Policy and Confidentiality
CMSC is committed to honoring the privacy of participants in educational activities. Our full privacy policy is available on our website at http://www.mscare.org/privacy.aspx
Other Information
Jointly sponsored by the Consortium of Multiple Sclerosis Centers and Delaware Media Group.This continuing education publication is supported by an educational grant from Teva CNS.For questions relating to CME, please contact the CMSC at (201) 487-1050 or email [email protected].
Hardware/Software Requirements
The minimum requirements for viewing an on-line book is an active internet connection and Flash (free software from Adobe) version 10 or higher.
Link to the Program
Agree Button
~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT and up to date, with MS News and Information
Sign-up for our Bi-Monthly eNewsletters 

.

WATCH OUR MS EDUCATIONAL VIDEOS by Topic, 

.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews